Download PDF
Pharmacopsychiatry 2004; 37(4): 180-188
DOI: 10.1055/s-2004-827175
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

Pharmacokinetics of m-Chlorophenylpiperazine after Intravenous and Oral Administration in Healthy Male Volunteers: Implication for the Pharmacodynamic Profile

A. Feuchtl1 , M. Bagli1 , R. Stephan1 , C. Frahnert1 , H. Kölsch1 , K.-U. Kühn1 , M. L. Rao1
  • 1Department of Psychiatry, University of Bonn, Germany
Further Information

Publication History

Received: 27.3.2003 Revised: 9.5.2003

Accepted: 3.7.2003

Publication Date:
01 July 2004 (online)

Also available at
    Permissions and Reprints

Introduction: Serotonin plays an important role in psychiatric diseases, most notably in depression and anxiety. Seven different major serotonin receptor subtypes have been described. Receptor-selective agonists and antagonists have been searched for to find a suitable drug to test the in vivo receptor sensitivity. Different serotonin receptor subtypes take part in the control of neuroendocrine function. m-Chlorophenylpiperazine (mCPP) acts as an agonist to serotonin 2C, 1A, 1B, and 1D receptor subtypes and is applied in challenge tests. The object of this study was to develop a pharmacokinetic-pharmacodynamic model to describe the effects of mCPP on pituitary hormone secretion. Methods: The hormone and mCPP plasma concentrations were determined after intravenous and oral administration of mCPP to 12 healthy men. The kinetic parameters of mCPP were compared to the drug’s effect on hormonal response. Results: After mCPP treatment, ACTH, cortisol, and prolactin levels were significantly increased compared to placebo. There was also a significant increase in clinical response (anxiety, shivering, dizziness, heightened sensitivity toward light and noise, and fear of losing control). Maximum mCPP concentrations varied 2.3-fold after intravenous infusion and 8-fold after oral administration. The absolute bioavailability ranged from 12 % to 84 %. mCPP’s elimination half-life ranged from 2.4 h to 6.8 h after intravenous infusion and from 2.6 h to 6.1 h after oral application. However, the kinetic data as well as the pharmacodynamic response varied to an extent that precluded pharmacokinetic-pharmacodynamic modeling. The wide interindividual variability in mCPP’s disposition kinetics could not be fully explained by genetic variation of the mCPP-metabolizing enzyme cytochrome P4502D6, which was determined in all probands. Discussion: Other factors contributing to the variability in disposition kinetics could not be ruled out in this study, suggesting that mCPP is not a suitable model drug to test serotonin 2C receptor activity in vivo.

References

  • 1 Akaike A. Posterior probabilities for choosing a regression model.  Annal Instit Math Stats. 1965;  30 A9-A13
    PubMedGoogle Scholar
  • 2 Aitken R CB. Measurement of feelings using visual analogue scales.  Royal Soc Med. 1969;  62 989-993
    PubMedGoogle Scholar
  • 3 Bagli M, Süverkrüp R, Rao M L, Bode H. Mean input times of three oral chlorprothixene formulations assessed by an enhanced least-square deconvolution method.  J Pharm Sci. 1996;  85 434-439
    CrossrefPubMedGoogle Scholar
  • 4 Bagli M, Süverkrüp R, Quadflieg R, Höflich G, Kasper S, Möller H J, Langer M, Barlage U, Rao M L. Pharmacokinetic-pharmacodynamic modeling of tolerance to the prolactin-secreting effect of chlorprothixene after different modes of drug administration.  J Pharmacol Exp Ther. 1999;  291 547-554
    PubMedGoogle Scholar
  • 5 Barr L C, Goodman W K, Price L H, McDougle C J, Charney D S. The serotonin hypothesis of obsessive compulsive disorder: Implications of pharmacologic challenge studies.  J Clin Psychiatry. 1992;  53 (4, Suppl.) 17-28
    PubMedGoogle Scholar
  • 6 Bullinger M, Heinisch M, Ludwig M, Geier S. Skalen zur Erfassung des Wohlbefindens: Psychometrische Analysen zum ”Profile of Mood States” (POMS) und zum ”Psychological General Well-Being Index” (PGWB).  Z Diff Diag Psychol. 1990;  11 53-61
    PubMedGoogle Scholar
  • 7 Charney D S, Woods S W, Goodman W K, Heninger G R. Serotonin function in anxiety. II. Effects of the serotonin agonist mCPP in panic disorder patients and healthy subjects.  Psychopharmacology. 1987;  92 14-24
    CrossrefPubMedGoogle Scholar
  • 8 Cutler D J. Theory of the mean absorption time, an adjunct to conventional bioavailability studies.  J Pharm Pharmacol. 1978;  30 476-478
    PubMedGoogle Scholar
  • 9 Eichelbaum M, Bertilsson L, Sawe J, Zekorn C. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.  Clin Pharmacol Ther. 1982;  31 184-186
    PubMedGoogle Scholar
  • 10 Gabrielson J, Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. Stockholm; Swedish Pharmaceutical Press 1994
    Google Scholar
  • 11 Gibaldi M, Perrier D. Pharmacokinetics. 2nd edn New York-Basel; Marcel Dekker 1982
    Google Scholar
  • 12 Gijsman H J, van Gerven J MA, Tieleman M C, Schoemaker R C, Pieters M SM, Ferrari M D, Cohen A F, van Kempen G MJ. Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers.  J Clin Psychopharmacol. 1998;  18 289-295
    CrossrefPubMedGoogle Scholar
  • 13 Hamik A, Peroutka S J. 1-(m-Chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain.  Biol Psychiatry. 1989;  25 569-575
    CrossrefPubMedGoogle Scholar
  • 14 Hamilton M. HAMA. Hamilton anxiety scale. In W. Guy (Ed) ECDEU Assessment Manual for Psychopharmacology. Rockville; National Institute of Mental Health 1976a: pp. 193-198
    Google Scholar
  • 15 Hamilton M. HAMD. Hamilton depression scale. In W. Guy (Ed) ECDEU Assessment Manual for Psychopharmacology. Rockville; National Institute of Mental Health 1976b: pp. 179-192
    Google Scholar
  • 16 Kahn R S, Davidson M. Serotonin receptor responsivity in schizophrenia.  Int Clin Pharmacol. 1993;  8 (Suppl. 2) 47-51
    PubMedGoogle Scholar
  • 17 Kahn R S, Wetzler S. m-Chlorophenylpiperazine as a probe of serotonin function.  Biol Psychiatry. 1991;  30 1139-1166
    CrossrefPubMedGoogle Scholar
  • 18 Kahn R S, Wetzler S, Asnis G M, King M A, Suckow R F, van Praag H M. Effects of m-chlorophenylpiperazine in normal subjects: a dose-response study.  Psychopharmacology. 1990;  100 339-344
    PubMedGoogle Scholar
  • 19 Kahn R S, Wetzler S, Asnis G M, King M A, Suckow R F, van Praag H M. Pituitary hormone responses to meta-chlorophenylpiperazine in panic disorder and healthy control subjects.  Psychiatry Res. 1991;  37 25-34
    CrossrefPubMedGoogle Scholar
  • 20 Kühn K U, Quednow B B, Bagli M, Meyer K, Feuchtl A, Krüger J, Frahnert C, Maier W, Rao M L. Allelic variants of the serotonin2C receptor agonist m-chlorophenylpiperazine in healthy male volunteers.  Pharmacopsychiatry. 2002;  35 226-230
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Lappalainen J, Zhang L, Dean M, Oz M, Ozaki N, Yu D H, Virkkunen M, Weight F, Linnoila M. Goldman D. Identification, expression, and pharmacology of Cys 23-Ser23 substitution in the human 5-HT2C receptor gene (HTR2C).  Genomics. 1995;  27 274-279
    CrossrefPubMedGoogle Scholar
  • 22 Lawlor B A, Sunderland T, Hill J L, Mellow A M, Molchan S E, Mueller E A, Jacobsen F M, Murphy D L. Evidence for a decline with age in behavioral responsivity to the serotonin agonist, m-chlorophenylpiperazine, in healthy human subjects.  Psychiatry Res. 1989;  29 1-10
    CrossrefPubMedGoogle Scholar
  • 23 Lawlor B A, Sunderland T, Mellow A M, Hill J L, Molchan S E, Murphy D L. Hyperresponsivity to the serotonin agonist, m-chlorophenylpiperazine, in Alzheimer's disease.  Arch Gen Psychiatry. 1989;  46 542-549
    PubMedGoogle Scholar
  • 24 Lewin H A, Stewart-Haynes J A. A simple method for DNA extraction from leukocytes for use in PCR.  Biotechniques. 1992;  13 522-524
    PubMedGoogle Scholar
  • 25 Lohmann P L, Bagli M, Krauss H, Müller D J, Schulze T G, Held T, Fangerau H, Maier W, Rietschel M, Rao M L. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients. Pharmacopsychiatry 2003 in press
    Google Scholar
  • 26 Miller R L, DeVane C L. Analysis of trazodone and m-chlorophenylpiperazine in plasma and brain tissue by high-performance liquid chromatography.  J Chromatogr. 1986;  374 388-393
    PubMedGoogle Scholar
  • 27 Murphy D L, Mueller E A, Hill J L, Tolliver T J, Jacobsen F M. Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers.  Psychopharmacology. 1989;  98 275-282
    CrossrefPubMedGoogle Scholar
  • 28 Riegelmann S, Collier P. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time.  J Pharmacokin Biopharm. 1980;  8 509-534
    CrossrefPubMedGoogle Scholar
  • 29 Rotzinger S, Fang J, Coutts R T, Baker G B. Human CYP2D6 and metabolism of m-chlorophenylpiperazine.  Biol Psychiatry. 1998;  44 1185-1191
    CrossrefPubMedGoogle Scholar
  • 30 Schwartz P J, Murphy D L, Wehr T A, Garcia-Borreguero D, Oren D A, Moul D E, Ozaki N, Snelbaker A J, Rosenthal N E. Effects of meta-chlorophenylpiperazine infusions in patients with seasonal affective disorder and healthy control subjects.  Arch Gen Psychiatry. 1997;  54 375-385
    PubMedGoogle Scholar
  • 31 Silverstone P H, Cowen P J. The 5-HT3 agonist, BRL 46 470 does not attenuate m-chlorophenylpiperazine (mCPP)-induced changes in human volunteers.  Biol Psychiatry. 1994;  36 309-316
    CrossrefPubMedGoogle Scholar
  • 32 Silverstone P H, Rue J E, Franklin M, Hallis K, Camplin G, Laver D, Cowen P J. The effects of administration of mCPP on psychological, cognitive, cardiovascular, hormonal and MHPG measurements in human volunteers.  Int Clin Psychopharmacol. 1994;  9 173-178
    PubMedGoogle Scholar
  • 33 Yamaoka K, Nakagawa T, Uno T. Statistical moments in pharmacokinetics.  J Pharmacokin Biopharm. 1978a;  6 547-558
    CrossrefPubMedGoogle Scholar
  • 34 Yamaoka K, Nakagawa T, Uno T. Application of the Akaike information criterion AIC in the evaluation of linear pharmacokinetics.  J Pharmacokin Biopharm. 1978b;  6 165-175
    CrossrefPubMedGoogle Scholar

Marie Luise Rao, PhD.

Department of Psychiatry

University of Bonn

Sigmund-Freud-Straße 25

D-53105 Bonn

Germany

Email: m.l.rao@uni-bonn.de

      >